Skip to main content

HubXchange

HubXChange logo

Antibody Drug Conjugate Therapeutics Xchange - Boston - 2025

Page Banner 1

Loading
  1. Cytotoxic Payload
    Reducing resistance of cancer cells to payloads
    • Cytotoxic Payload
  2. Cytotoxic Payload
    Poster Presentation:
    • Cytotoxic Payload
  3. Networking Lunch
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
  4. Evening Drinks Reception
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
  5. Linker Design
    Designing linkers to achieve controlled release of cytotoxic drugs with specificity and efficiency
    • Linker Design
    Paul Jaminet
    Paul Jaminet, Founder & President - Angiex
  6. Toxicity & Off-Target Effects
    Reducing systemic toxicity following release of cytotoxic drugs after internalization and cleavage of the linker harming normal tissues expressing low levels of the target antigen
    • Toxicity & Off-Target Effects
    Kyle Fitzgerald
    Kyle Fitzgerald, Associate Director - Mythic Therapeutics
  7. Target Selection
    Maximizing ADC effectiveness against reduced expression of the target antigen
    • Target Selection
    Victor Goldmacher
    Victor Goldmacher, Chief Scientific Officer - ImmuVia
  8. Target Selection
    Poster Presentation:
    • Target Selection
  9. Linker Design
    Poster Presentation:
    • Linker Design
  10. Afternoon Refreshments
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
  11. Toxicity & Off-Target Effects
    Poster Presentation:
    • Toxicity & Off-Target Effects
  12. 1-2-1 Meetings / Networking Break
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
  13. 1-2-1 Meetings / Networking Break
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
  14. Spotlight Presentation:
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
  15. Registration
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
  16. Cytotoxic Payload
    Sponsor-Led Roundtable:
    • Cytotoxic Payload
  17. Linker Design
    Sponsor-Led Roundtable:
    • Linker Design
     
  18. Toxicity & Off-Target Effects
    Sponsor-Led Roundtable:
    • Toxicity & Off-Target Effects
  19. Target Selection
    Sponsor-Led Roundtable:
    • Target Selection
  20. Morning Refreshments
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
  21. Cytotoxic Payload
    Developing potent and safe cytotoxins to reduce severe side-effects
    • Cytotoxic Payload
    Gastón Soria
    Gastón Soria, Co-Founder & Chief Scientific Officer
  22. 1-2-1 Meetings / Networking Break
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
  23. Linker Design
    Ensuring stability of linker to prevent premature release of payload causing off-target toxicity [Topic TBC]
    • Linker Design
    Sujiet Puthenveetil
    Sujiet Puthenveetil, Director - AstraZeneca
  24. 1-2-1 Meetings / Networking Break
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
  25. Toxicity & Off-Target Effects
    Overcoming immunogenicity which could limit the effectiveness of ADCs causing adverse reactions
    • Toxicity & Off-Target Effects
  26. Target Selection
    Finding cancer-specific or cancer-enriched antigens that are not expressed on normal healthy tissues to avoid off-target toxicity
    • Target Selection
    Zhinan Xia
    Zhinan Xia, Chief Scientific Officer - Abimmune Bio
  27. Opening Address & Keynote Presentation:
    • Target Selection
    • Toxicity & Off-Target Effects
    • Linker Design
    • Cytotoxic Payload
Search